Abstract: Disclosed is tri- or tetravalent sialic acid derivatives comprising a core moiety to which 3 or 4 sialic acid residues are connected via a linker. Such derivatives inhibit the binding of adenovirus to human cells, whereby infections, such as epidemic keratoconjunctivitis, may be treated or prevented by administration of the tri- or tetravalent sialic acid derivatives.
Type:
Grant
Filed:
August 28, 2014
Date of Patent:
July 3, 2018
Assignee:
ADENOVIR PHARMA AB
Inventors:
Niklas Arnberg, Rémi Caraballo, Mikael Elofsson
Abstract: Disclosed is tri- or tetravalent sialic acid derivatives comprising a core moiety to which 3 or 4 sialic acid residues are connected via a linker. Such derivatives inhibit the binding of adenovirus to human cells, whereby infections, such as epidemic keratoconjunctivitis, may be treated or prevented by administration of the tri- or tetravalent sialic acid derivatives.
Type:
Application
Filed:
August 28, 2014
Publication date:
July 21, 2016
Applicant:
Adenovir Pharma AB
Inventors:
Niklas Arnberg, Rémi Caraballo, Mikael Elofsson
Abstract: Herein are disclosed novel compounds according to Formula (I) and aggregates comprising such compounds. These aggregates are useful to treat and prevent ocular infections caused by a vims, which virus binds to terminal sialic residues present on the cell surface of the cell to be infected by the virus.
Type:
Grant
Filed:
July 5, 2010
Date of Patent:
August 12, 2014
Assignee:
Adenovir Pharma AB
Inventors:
Olov Sterner, Ulf Ellervik, Karolina Aplander, Anders Carlsson
Abstract: Herein are disclosed novel compounds according to Formula (I) and aggregates comprising such compounds. These aggregates are useful to treat and prevent ocular infections caused by a vims, which virus binds to terminal sialic residues present on the cell surface of the cell to be infected by the virus.
Type:
Application
Filed:
July 5, 2010
Publication date:
May 24, 2012
Applicant:
ADENOVIR PHARMA AB
Inventors:
Olov Sterner, Ulf Ellervik, Karolina Aplander, Anders Carlsson
Abstract: Adenoviral infections and in particular ocular adenoviral infections, e.g. keratoconjunctivitis, can be treated or alleviated by the administration of a substance, interfering with the interaction between the virus and the sialic acid receptor, in a therapeutically effective amount.
© 2025 Justia
